Combined Treatment of Heterocyclic Analogues and Benznidazole upon Trypanosoma cruzi In Vivo
Open Access
- 26 July 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (7), e22155
- https://doi.org/10.1371/journal.pone.0022155
Abstract
Chagas disease caused by Trypanosoma cruzi is an important cause of mortality and morbidity in Latin America but no vaccines or safe chemotherapeutic agents are available. Combined therapy is envisioned as an ideal approach since it may enhance efficacy by acting upon different cellular targets, may reduce toxicity and minimize the risk of drug resistance. Therefore, we investigated the activity of benznidazole (Bz) in combination with the diamidine prodrug DB289 and in combination with the arylimidamide DB766 upon T. cruzi infection in vivo. The oral treatment of T.cruzi-infected mice with DB289 and Benznidazole (Bz) alone reduced the number of circulating parasites compared with untreated mice by about 70% and 90%, respectively. However, the combination of these two compounds decreased the parasitemia by 99% and protected against animal mortality by 100%, but without providing a parasitological cure. When Bz (p.o) was combined with DB766 (via ip route), at least a 99.5% decrease in parasitemia levels was observed. DB766+Bz also provided 100% protection against mice mortality while Bz alone provided about 87% protection. This combined therapy also reduced the tissular lesions induced by T. cruzi infection: Bz alone reduced GPT and CK plasma levels by about 12% and 78% compared to untreated mice group, the combination of Bz with DB766 resulted in a reduction of GPT and CK plasma levels of 56% and 91%. Cure assessment through hemocultive and PCR approaches showed that Bz did not provide a parasitological cure, however, DB766 alone or associated with Bz cured ≥13% of surviving animals.This publication has 56 references indexed in Scilit:
- Brazilian Green Propolis: EffectsIn VitroandIn VivoonTrypanosoma cruziEvidence-Based Complementary and Alternative Medicine, 2011
- Arylimidamide DB766, a Potential Chemotherapeutic Candidate for Chagas' Disease TreatmentAntimicrobial Agents and Chemotherapy, 2010
- Novel Arylimidamides for Treatment of Visceral LeishmaniasisAntimicrobial Agents and Chemotherapy, 2010
- New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289Antimicrobial Agents and Chemotherapy, 2009
- Perspectives on Trypanosoma cruzi–Induced Heart Disease (Chagas Disease)Progress in Cardiovascular Diseases, 2009
- Oral Transmission of Chagas Disease by Consumption of Açaí Palm Fruit, BrazilEmerging Infectious Diseases, 2009
- In Vitro and In Vivo Studies of the Trypanocidal Activity of a Diarylthiophene Diamidine against Trypanosoma cruziAntimicrobial Agents and Chemotherapy, 2008
- Drug-induced cure drives conversion to a stable and protective CD8+ T central memory response in chronic Chagas diseaseNature Medicine, 2008
- Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in miceLife Sciences, 2004
- Is TNFα involved in early susceptibility of Trypanosoma cruzi-infected C3H/He mice?Research in Immunology, 1991